Gene Therapy 'Cassettes' Could Speed, Cheapen Manufacturing, Gottlieb Says
Executive Summary
US FDA Commissioner teases endpoints, suggests accelerated approval plan and post-marketing considerations for gene therapies targeting hemophilia.
You may also be interested in...
Individualized Gene Therapy: US FDA Considering Device-Like Manufacturing Approval Process
CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.
US FDA Will Allow Transitioning Products To Continue Referencing Drug Master Files
The 'technical detail' needed to be resolved in part to ensure there would be no shortages after the 2020 change from regulation as drugs to biologics for certain protein products, the agency said.
US FDA Will Allow Transitioning Products To Continue Referencing Drug Master Files
The 'technical detail' needed to be resolved in part to ensure there would be no shortages after the 2020 change from regulation as drugs to biologics for certain protein products, the agency said.